Search research articles
Contact Us
Filters
Showing results (201-210 of 222) with videos related to
Page
of 23
Sort By:
Journal of Medicinal Chemistry
|
December 24, 2008
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist
David A Griffith, John R Hadcock, Shawn C Black, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 3, 2021
Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO)
Carol H Hu, Meriah W Neissel Valente, O Scott Halpern, et al.
International Journal of Molecular Sciences
|
January 11, 2022
Modulation by 17,20S(OH)<sub>2</sub>pD of Fibrosis-Related Mediators in Dermal Fibroblast Lines from Healthy Donors and from Patients with Systemic Sclerosis
Monica L Brown Lobbins, Andrzej T Slominski, Karen A Hasty, et al.
ACS Medicinal Chemistry Letters
|
June 17, 2026
Solubility-Driven Lead Optimization of PAR4 Antagonists and Evaluation of a Phosphate Ester Prodrug Delivery Strategy
O Scott Halpern, Samuel K Reznik, Xiaojun Zhang, et al.
International Journal of Molecular Sciences
|
August 27, 2021
17,20S(OH)<sub>2</sub>pD Can Prevent the Development of Skin Fibrosis in the Bleomycin-Induced Scleroderma Mouse Model
Monica L Brown Lobbins, Imara-Safi O Scott, Andrzej T Slominski, et al.
Frontiers in Pharmacology
|
February 11, 2021
Netosis and Inflammasomes in Large Vessel Occlusion Thrombi
Stephanie H Chen, Xavier O Scott, Yoandy Ferrer Marcelo, et al.
Biochemical and Biophysical Research Communications
|
March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity
John R Hadcock, David A Griffith, Phillip A Iredale, et al.
Plos One
|
December 19, 2009
Mechanisms underlying metabolic and neural defects in zebrafish and human multiple acyl-CoA dehydrogenase deficiency (MADD)
Yuanquan Song, Mary A Selak, Corey T Watson, et al.
Journal of Medicinal Chemistry
|
April 9, 2009
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity
Robert L Dow, Philip A Carpino, John R Hadcock, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 9, 2005
A new chemical tool for exploring the physiological function of the PDE2 isozyme
Robert J Chambers, Kristin Abrams, Norman Y Garceau, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 222) with videos related to
Sort By:
Page
of 23
Journal of Medicinal Chemistry
|
December 24, 2008
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist
David A Griffith, John R Hadcock, Shawn C Black, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 3, 2021
Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO)
Carol H Hu, Meriah W Neissel Valente, O Scott Halpern, et al.
International Journal of Molecular Sciences
|
January 11, 2022
Modulation by 17,20S(OH)<sub>2</sub>pD of Fibrosis-Related Mediators in Dermal Fibroblast Lines from Healthy Donors and from Patients with Systemic Sclerosis
Monica L Brown Lobbins, Andrzej T Slominski, Karen A Hasty, et al.
ACS Medicinal Chemistry Letters
|
June 17, 2026
Solubility-Driven Lead Optimization of PAR4 Antagonists and Evaluation of a Phosphate Ester Prodrug Delivery Strategy
O Scott Halpern, Samuel K Reznik, Xiaojun Zhang, et al.
International Journal of Molecular Sciences
|
August 27, 2021
17,20S(OH)<sub>2</sub>pD Can Prevent the Development of Skin Fibrosis in the Bleomycin-Induced Scleroderma Mouse Model
Monica L Brown Lobbins, Imara-Safi O Scott, Andrzej T Slominski, et al.
Frontiers in Pharmacology
|
February 11, 2021
Netosis and Inflammasomes in Large Vessel Occlusion Thrombi
Stephanie H Chen, Xavier O Scott, Yoandy Ferrer Marcelo, et al.
Biochemical and Biophysical Research Communications
|
March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity
John R Hadcock, David A Griffith, Phillip A Iredale, et al.
Plos One
|
December 19, 2009
Mechanisms underlying metabolic and neural defects in zebrafish and human multiple acyl-CoA dehydrogenase deficiency (MADD)
Yuanquan Song, Mary A Selak, Corey T Watson, et al.
Journal of Medicinal Chemistry
|
April 9, 2009
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity
Robert L Dow, Philip A Carpino, John R Hadcock, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 9, 2005
A new chemical tool for exploring the physiological function of the PDE2 isozyme
Robert J Chambers, Kristin Abrams, Norman Y Garceau, et al.
Page
of 23